Myto Therapeutics develops novel small-molecules that ameliorate orphan mitochondrial diseases, including Friedreich's ataxia and Leigh Syndrome. Our patented technology delivers bioactive monomethyl fumarate molecules with superior pharmacokinetics (PK) to other marketed prodrugs. The superior PK of our molecules underlies their greater pharmacodynamic potency to ameliorate mitochondrial diseases. The Mechanism of Action of our MYT-109 suggests it is a 'platform' drug, which could treat multiple mitochondrial diseases.